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ABSTRACT 
In causalgia (a sympathetic mediated pain syndrome), 
pain appears to be mediated by the upregulation of cx1 
adrenergic receptors on the primary afferents of the 
peripheral nerves. 
Considering the limitations of the existing treatment, 
it is postulated that an a 1 adrenoreceptor antagonist, 
terazosin, when delivered locally at a site distal to the 
nerve injury by transdermal iontophoresis will produce pain 
relief. Iontophoresis is a noninvasive and a rate controlled 
drug delivery system. 
A sensitive analytical technique for terazosin (TRZ) in 
plasma was developed using a cyanopropyl solid phase 
extraction technique and high performance liquid 
chromatography with fluorescence detection. Analysis of 
spiked plasma samples indicated no significant differences 
(p > 0. OS) in intra- and inter-day variations. The Solid 
Phase Extraction (SPE) procedure yielded a complete recovery 
of TRZ from plasma samples, enabling the detection of 
concentration as low as 0.05 ng/mL. The method was used to 
quantify TRZ from plasma after an intraperitoneal dose in a 
rat model. 
Results from in vitro and in vivo experiments suggested 
that the iontophoretic delivery of TRZ was significantly 
higher than the passive delivery (p < 0.05, and TRZ 
degradation was prevented by the incorporation of a salt-
bridge in the electrode assembly. 
It is widely regarded that iontophoresis of small 
molecular weight ionic compounds have similar pharmacokinetic 
profile to those administered parenterally. This implies that 
iontophoresis overcomes the rate limiting barrier (the 
stratum corneum) and the drug appears in blood immediately 
following deli very. However, in our studies, peak plasma 
concentration is reached in approximately 1.5 hours after a 
ten minute iontophoresis, suggesting a drug depot formation 
in the skin. The nature (bound/free form) and the exact site 
of reservoir formation is not yet known. It may be possible 
to take therapeutic advantage of such a reservoir effect to 
establish skin depot that is slowly absorbed over time. 
Key WordS:causalgia, iontophoresis, solid phase extraction, 
terazosin, salt-bridge, depot formation. 
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1 . 0 GENERAL INTRODUCTION 
1. 1 Statement of Research Problem 
1 
Causalgia is a painful syndrome arising from partial 
nerve injury caused by a high velocity projectile (e.g., a 
bullet wound} striking any part of the peripheral limb. Pain 
appears distal to the site of injury (i.e., the hand or the 
foot) is usually severe and is often described as burning, 
stabbing and tearing in quality (Sato and Perl, 1991; Price et 
al., 1989). Characteristically, this is accompanied by 
allodynia, hyperalgesia, hyperpathia and can be aggravated by 
variety of emotional and physical stDmuli (Bonica, 1990a) . 
Unlike pain due to extensive nonneural tissue damage which 
often subsides within few weeks, causalgic pain persists for 
several months to years (Price et al., 1992). 
In causalgia, the activity in sympathetic efferent 
neurons can exacerbate pain (McMahan, 1991) . These patients 
are often said to have sympathetically maintained pain (SMP) . 
The diagnosis of the disease is obscure and requires a 
complete patient history as well as physical and psychological 
evaluations of the patient {Roger and Valley, 1994) . The 
diagnosis depends upon the symptoms (burning pain, allodynia 
and hyperpathia}, signs (edema, sweating profile, temperature 
changes), objective measurements (e.g., skin temperature, 
radiographs, and triple phase bone scans) and clinical 
2 
improvement following sympathetic blockade (Roger and Valley, 
1994) or phentolamine infusion (Raja et al., 1991). 
In general, management of causalgia involves treating 
the precipitating injury (cleaning of wound) followed by 
sympathetic blockade (Hannington and Kiff, 1974) and 
aggressive physiotherapy (Bonica, 1990a). Intravenous regional 
sympathetic blockade with local anaesthetics or guanethidine 
(Nathan and Loh, 1978) produces prompt relief. The success of 
sympathetic blockade depends on: (1) the timing of the block 
in relation to the onset of pain; (2) the skill of the 
physician; and (3) the completeness of sympathetic block. 
However, the injection of sympathetic blocking agents is 
painful, the relief obtained lasts only a few days, and 
repeated blocks are required (Bonica, 1990a) . Repeated 
injections not only produce local tissue damage, but also have 
potential side effects (Loofstrom and Cousin, 1988) including 
hypotension, nausea, vomiting, urinary retention and 
convulsions. When these methods fail, sympathectomy is carried 
out using either the chemical or surgical methods depending 
upon the condition of the patient. Surgical removal of the 
sympathetic ganglia in an otherwise healthy patients can 
produce long lasting relief, but it is not always successful. 
Treatment of emaciated patients with chemical sympathectomy 
produces only transient relief. 
Other treatment strategies include transcutaneous nerve 
stimulation, direct neural peripheral nerve or dorsal column 
3 
stimulations. Relief of pain by these treatments was reported 
by Ordag eta~. (1987), but large controlled studies are not 
available to assess their long term efficacies. Several 
adjunct agents such as antidepressants with analgesic 
properties independent of their mood altering properties 
(Kishore et a~., 1990; Tura and Tura, 1990) and opiods (Becker 
et a~., 1995) are beneficial. Based on the up regulation of a 
receptors on the primary afferents of the injured peripheral 
nerves, oral adrenergic antagonists have been tried (Sato and 
Perl, 1991; Sato et. al., 1993; Koltezenburg., 1989). Oral 
treatment with prazosin was effective in humans at a dose of 
8 mg/day, but the systemic adverse effects such as orthostatic 
hypotension, dizziness, tachycardia, impotence, blurred vision 
(AHFS, 1996) and frequent drug administration limit (Abram and 
Lightfoot, 1981) its long ter.m usefulness. Thus in humans, the 
need for a number of approaches to treat causalgia have been 
attempted with some success, but the vast majority of patients 
are inadequately controlled by the available therapy. 
1.2 Specific Hypothesis of SMP. 
1.2.1 Adrenergic Receptors on the Pr~ry Sensory Neurons 
Clinical evidence for the involvement of an a-adrenergic 
mechanism in causalgia is evident from the pain relief 
obtained in humans following the infusion of phenoxybenzamine 
(Ghostine et a~., 1984) or phentolamine (Raja et al., 1991) 
4 
and by the oral prazosin administration (Abram and Lightfoot, 
1981} . 
Wall and Gutnick (1974) have noted that many myelinated 
and unmyelinated regenerating efferents in an animal model of 
neuropathic pain develop ongoing activity. This is 
dramatically increased by local administration of 
norepinephrine, or by stimulation of the lumber sympathetic 
chain (Devor and Janig, 1981) and is blocked by ~ adrenergic 
antagonists, but not by ~ adrenergic antagonists (Scadding, 
1982). These results suggest that the damage nociceptive 
neurons triggers the expression of ex-adrenergic receptors 
(Sato and Perl, 1991; Sato et. a~., 1993; Koltezenburg., 1989; 
Treede et a~., 1992; Campbell et a~., 1988, 1992). It is 
believed that catecholamines, released from the sympathetic 
efferent fibers bind to these receptors producing 
depolarization. Repetitive activity sets off spike propagation 
along the sensory neurons to the spinal cord. This peripheral 
link between sympathetic efferents and sensory neurons can be 
enhanced and maintained by somatosympathetic reflexes, whereby 
nociceptive afferent input evokes local sympathetic efferent 
activity over multiple spinal segments (Beacham and Perl, 
1964; Blinn eta~., 1980). The sympathetic efferent activity 
stimulation enhances the sensitivity of the nociceptor by 
5 
causing vasoconstriction, ischemia, and alteration in vascular 
permeability. Sensitivity is further enhanced by the direct 
action of locally released substances like substance P, PGs, 
and bradykinins (Pierce et al., 1996). 
Several patients treated with oral prazosin, an cx1 -
antagonist showed improvement in pain, swelling and 
vasoconstriction (McLesky, 1983). Significant pain reduction 
was obtained with oral prazosin in a patient with recurrent 
foot pain, previously untreatable to surgical sympathectomy 
(Abram and Lightfoot, 1981) . Oral and topical application of 
an a:2-agonist, clonidine, was also effective presumably by 
inhibiting norepinephrine release (Glynn and Jones, 1990; 
Davis et al., 1990). However, the systemic effect of these 
drugs limit their long term use. 
These results favour the involvement of a 1 receptors, and 
local delivery of an a 1 antagonist by transdermal iontophoresis 
may provide a convenient and effective method of pain control 
without producing predominant systemic actions. The dose of 
terazosin can easily be controlled by varying the strength of 
current and the time of delivery. 
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1.3 Introduction to Iontophoresis 
The penetration of substances through the skin has long 
been used as the method for the administration of drugs to 
achieve a local, or a systemic action. Drugs such as 
scopolamine (Hyoscine~), nitroglycerin (Transdermal-Nitro®), 
estradiol (Estraderm.®) , and clonidine (Catapress®) are now 
commercially available as transdermal patches. However, some 
drugs when delivered passively ionize at skin pH, which result 
in a poor permeability across the skin (Sloan and Soltani, 
1986) . The number of solutes delivered systemically by 
transdermal iontophoresis is limited by the barrier properties 
of stratum corneum, the outermost layer. As a result, the 
conventional delivery systems are limited to highly potent, 
small lipophilic drug molecules. 
Iontophoresis has the potential to overcome the 
limitations of conventional transdermal systems making it 
feasible to deliver ionic, hydrophilic and some of the high 
molecular weight compounds (Burnette, 1989; Sloan and Soltani, 
198 6) • 
Iontophoresis is a process whereby ionic molecules are 
transported into tissues by the passage of a direct electric 
current. The iontophoretic device (Figure 1.1) consists of 
three basic components: (a) a constant current source; (b) an 
7 
{a) current source 
+ 
(c) inactive electrode 
Skin (b) active electrode 
Drug (D+, A-) Buffer ions (It A-) 
+ 
Anion (e.g., Ci) 
BLOOD 
Figure 1.1 A Typi~ Iontophoretic De1ivery System: The device 
shown can be easily mounted on the appendage such as the ar.m. 
It is assumed that under the electrodes exists an aqueous 
solution which on one side contains a positively charged drug 
(D+) and its counter ion (A-). The drug is assumed to act as 
its own buffer. Under the cathode exists a buffer which is 
designated in its dissociated form as H+ and A-. Extracellular 
ions, primarily Na+ and cl- exist beneath the skin (Adapted 
from Burnette, 1989) . 
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active reservoir containing the drug; and (c) an inactive 
reservoir. The drug in solution is delivered from an electrode 
of the same charge, and an oppositely charged electrode is 
placed at a neutral site (site where no therapeutic action is 
desired) on the body surface. When the device is activated, 
transport of charged molecules occurs across the skin 
primarily by electrostatic force of repulsion from the driving 
electrodes. 
Thus, the migration of ions through the skin due to the 
applied electric field can be expressed as ionic current using 
Faraday's law of electrochemistry: 
id . t .. F 
m =------ . . . . . . . .. . . . . .. .. .. . . . . . . . . . . . . . . . . Equation ( 1) 
z 
where: 
m = amount of drug delivered, id= strength of current carried 
by the drug ion, t = iontophoresis time, z = valency of drug 
ion , F = Faraday's constant. 
The fraction of current carried by each ion is called the 
transference or the transport number for that ion. The maximum 
transport for a given ion occurs when the transport number is 
unity, i.e., when the ion carries 100% of current across the 
membrane. The transport number of drug also represents the 
efficiency of the iontophoretic system. Mathematically, the 
9 
relationship between the drug flux ion and the drug transport 
number is: 
ti. I 
.............................. Equation (2) 
where: 
Ji = flux of drug ion, Zi = drug charge, t1. = transport number 
for the drug ion = id/I, id = current carried by drug ion, 
I= total current, F = Faraday's constant. 
From the above equations, the efficiency of drug delivery 
will depend upon the extraneous ion concentration in the donor 
reservoir. The extraneous ion concentration can be reduced to 
maximize the iontophoretic efficiency (Sanderson et al., 
1989) . During iontophoresis, oxidation and reduction reactions 
may occur at the anode and the cathode. These reactions 
produce new ions that contaminate the drug solution. However, 
a careful selection of anode or cathode materials, in 
combination with the selection of an appropriate drug counter 
ion, could significantly reduce the electrochemical 
contamination (Caris et al., 1990). Using a weaker salt of the 
drug (Phipps and Gyory, 1992) ( i.e., the acetate rather than 
hydrochloride salt) will improve the efficiency of drug 
delivery. The equilibrium between the weak anion and its 
corresponding acid will effectively prevent the pH in the 
10 
boundary layer from dropping below the PKa of the acid. Using 
acetate as an example, the pH in the boundary layer (equal to 
its pf<a of -4.7 5) is sufficiently high to minimize proton 
transport, in spite of the high ionic mobility of protons. 
Another modification is to increase the transport of 
drug ions at the expense of other ions by increasing the 
concentration of drug in the reservoir. This works to a point 
because, at higher concentrations the transport of the drug 
ion becomes independent of the drug concentration (Sanderson 
et a~., 1989). Alternatively, double disc electrodes have been 
used to increase the morphine flux compared to the single 
electrode model(Clemessy et al., 1994). The use of chemical 
penetration enhancers such as hydro-alcoholic solution and 
surfactants (Srinivasan et al. 1990) may also increase drug 
permeation. There are several factors that affect the 
iontophoretic flux are described in section 1.4 to 1.6 
1.4 Physiochemica1 Factors Affecting Iontophoresis 
1.4.1 pH of the Drug Solution 
The effect of vehicle pH on the rate and the extent of 
iontophoretic delivery of lidocaine through human stratum 
corneum was investigated by Siddiqui et al. (1985). The rate 
of penetration was greatest at the pH at which lidocaine 
11 
existed in the ionic form. The importance of pH in enhancing 
solute transport by iontophoresis was shown for other drug 
molecules such as insulin (Siddiqui et al., 1987a). A shift in 
pH becomes particularly important for protein and peptide 
drugs, since the pH of the solution determines the charge on 
these molecules (Siddiqui et al., 1987a, 1987b). Skin membrane 
ionization induced by pH change has been implicated to explain 
the anomalous behaviour of verapamil iontophoretic flux which 
increases with increasing the pH of the solution. The degree 
of drug ionization over the pH range was fairly constant (Behl 
et al., 1989). 
1.4.2 MOlecular Size of Drug Ion 
The permeability coefficient of a series of positively 
charged, negatively charged, and uncharged solutes across 
excised human skin was shown to depend on its molecular size 
(Yoshida and Roberts, 1992) . As the molecular size increases, 
the permeability coefficient of the drug decreases (Yoshida 
and Roberts, 1993; Green et al., 1991). A drug ion with a 
molal volume of 150 mL/mol, based on the free volume model 
(Potts and Guy, 1991), is considered optimal for the 
iontophoretic transport {Yoshida and Roberts, 1993). However, 
certain solutes of higher molal volumes were shown to 
12 
penetrate effectively across the skin and into the systemic 
circulation. (e.g., insulin, vasopressin, and certain growth 
hormones) 
1.4.3 Ion Competition for Iontophoretic Transport 
The condition of electro-neutrality in solution requires 
that an equal quantity of positively charged and negatively 
charged molecules exist in a given volume of solution. 
Therefore, the migrating ion requires an ion of opposite 
charge in close proximity. This oppositely charge ion is 
referred to as the counter-ion. An ion of like charge, but of 
different type is termed a co-ion. Effect of these competitive 
ions on solute transport was shown by Bellantone et a~. {1986) 
who observed the reduction in the benzoate flux to be more 
than half when an approximately equimolar amount of sodium 
chloride was added to the donor solution. Details of changes 
effecting ionic strength of the donor solution has been 
discussed by Lelawongs et a~. (1989). 
Use of divalent cations in drug solution is believed to 
diminish the selective per.mselectivity of skin towards cations 
by binding to negatively charged sites on the skin (Burnette 
and Ongipiattanakul, 1987). The ionic composition of the 
receptor solution can also alter the efficiency of drug ion 
13 
transport~ Replacing the competing ion (Cl-), with a 
polyacrylic acid yielded a transport efficiency of 80% (Phipps 
and Gyory, 1992) . 
1.5 For.mulation Factors Affecting Iontophoresis 
1.5.1 Current Strength and Types 
A linear relationship is observed between the flux of 
most compounds and the applied current. The permeability 
coefficient of benzoate increased linearly when the current 
strength was increased from 0.08 to 1.6 mA/cm2 (Bellantone et 
al., 1986) A linear increase in steady state flux with 
increasing current is reported for mannitol (Burnette and 
Ongipiattanakul, 1987), thyrotropin releasing hormone 
(Burnette and Marrec, 1986) and verapamil (Wearly et al., 
1989) . Similar correlation was observed for 5-fluorouracil 
penetration in the rabbit eye (Kondo and Ariie, 1989) . 
Stephan and co-workers (1984) have pointed the necessity 
of using constant current, rather than constant val tage. 
Because at constant voltage, impedance of the skin changes 
rapidly during iontophoresis, primarily by the introduction of 
ions into the skin. The presence of these ions in skin 
increases skin conductance due to low skin impedance and high 
current. If constant voltage is used, current that passes 
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through the skin is highly variable. Given the fact, that at 
least a part of this current flows through the shunt (sweat 
gland and hair follicles) pathway, current densities can be 
quite high resulting in tissue damage. There are several types 
of current used in iontophoretic delivery (Figure 1.2). For 
small molecules such as lidocaine, at frequency up to 1 kHz, 
no difference in the delivery rate was reported for pulse or 
continuous DC mode of delivery (Bagniefski and Burnette, 
1990). For large molecules such as insulin (Siddiqi et al., 
1987) and desmopressin (Nakakura et al., 1996), pulsed current 
seemed to produce higher delivery. However, questions do arise 
about the design of pulsed DC power source operating at 
frequency above 10 kHz (Okabe et al., 1986). At this 
frequency, electroporation of the drug can not be ruled out. 
Moreover, pulse DC system with 50% duty consumes twice the 
power of a continuous DC system. In most of the iontophoretic 
study constant DC current is used. But when used continuously 
over a period it produces skin polarization and irritation 
(Sanderson et al., 1987). Hirvonen et al. (1995) have 
evaluated different current profiles that affect the 
iontophoretic deli very of charged aminoacids. In terms of 
total transmembrane drug delivery, constant DC was the most 
efficient, pulsed DC with a comparable charge did not deliver 
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as much as the uninterrupted DC, while square-wave and sine-
wave AC profiles showed comparable transport rates. 
Another novel method is the use of Pt/Pt electrodes with 
DC reversing current (Kara et al., 1993 (Figure 1.2). This 
mode of delivery has several advantages. First, the pH change 
in the donor and the receptor solution is negligible (Figure 
1.3). Second, by reversing the electrode polarity, same drug 
or two different classes of drugs can be delivered 
simultaneously without physically mixing them. Third, the 
formation of vesicles and bullae that are basis for skin burns 
{Sanderson et al., 1987) are avoided by reversing the polarity 
of electrodes (Tapper, 1979) . However, an obvious question 
that arises from this mode of delivery is: will reversing 
current remove the drug already delivered into the skin? This 
is unlikely, as reversing current will remove those ions (like 
Na+, cl- etc.) from skin that have a higher transport number 
than the drug ion. 
1.5.2 E1ectrode ~s 
The choice of electrode is an important parameter for 
successful iontophoresis. If inert electrodes like platinum, 
carbon and graphite are used, electrolysis of water takes 
place at these electrodes, resulting in the formation of 
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Figure 1.2 Types of Iontophoretic Current 
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hydrogen ions at anode and hydroxyl ions at cathode (Figure 
3) . Formation of these ions affects the pH of drug solution, 
and thereby affecting the drug flux (Sanderson et al., 1987). 
Moreover, the hydrogen ion being charged and highly mobile 
competes with drug ion for transport. The use of buffer does 
little to solve the problem. However, it does prevent the pH 
change, but provides its own ion for transport. Thus, 
decreasing the efficiency of drug delivery. These difficulties 
associated with electrolysis reactions that occur with inert 
electrodes in direct current (DC) iontophoresis can be 
corrected by using a size exclusion membrane (Burnette and 
Ongipiattanakul, 1987). This membrane prevents direct drug 
solution interaction with the electrode. Replacing inert 
electrodes with Ag/AgCl that is consumed in the electrolysis 
(Figure 1.3) prevents the pH change. In addition, if drug 
molecules present in the system do not undergo redox reactions 
at Ag/AgCl electrode interface, the use of an Ag/AgCl 
electrode system provides a more convenient way to apply a 
voltage difference across the skin (if the total charge 
transfer across the electrodes during the experiment does not 
delete the AgCl deposited on the electrode) . 
The Ag/AgCl electrodes are expensive and need constant 
replacement. Continuous use of Ag/AgCl electrodes may result 
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E1ectrochemical Reactions: 
(i) Inert Electrodes (e.g., platinum electrodes) and DC 
Current 
Anode {+) 
Cathode {-) 
(ii) Reactive Electrodes (e.g., silver/silver chl.oride) and DC 
Current 
Anode (+) 
Ag~ + Cl- - AgCl + e 
Cathode (-) 
AgCl + e- - Ag + Cl-
(iii) Inert Electrodes with Reversing (every 5. 0 min) DC 
Current 
Either Electrodes 
W (from anode reaction) + 011 ( from cathode reaction) - no pH 
change in the drug solution 
Figure 1.3 Electrochemical Reactions at Different Electrodes 
with Different CUrrent Profiles. A novel way is the use of DC 
reversing current, the H+ formed at the anode would 
neutralize the pH effect of Ofr ion formed at the same 
electrode {after the reversal of polarity). The pH change 
during the five minute interval is insiqnificant. 
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in deposition of black silver chloride over the gray Ag/AgCl 
layer as a result of chlorination. Mechanical removal of the 
deposit is generally not recommended. In such cases, a five to 
one dilution of dilute ammonium hydroxide with distilled water 
has been used with success (Boucsein, 1992) . If a layer of 
bright silver appears, the electrodes can be rechlorinated, 
but the electrode layer is not uniformly composed of a 
sintered Ag/AgCl. 
Given the significance of electrodes in iontophoresis 
with regard to drug delivery and patient comfort, an alternate 
way is the use of Pt/Pt electrodes and DC reversing current as 
mentioned earlier in the discussion (1.5.1). 
1.6 B~oloqica1 Factors 
The iontophoretic fluxes of pyridostigmine and lithium 
through human, pig and rabbit skin are comparable (Phipps et 
al., 1989). Iontophoresis reduces intra- and inter-subject 
variation in drug delivery rate, which is unachievable with 
passive absorption studies. This is consistent with the 
studies of Burnette and Ongipiattanakul (1987} that observed 
comparable iontophoretic fluxes of sodium chloride and 
mannitol across human thigh skin obtained from the skin 
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regions of low and high density hair fo~licles. Insulin 
delivery from hairless rat skin was comparable to fuzzy rat 
(Siddiqui and Chien, 1987) . Moderate enhancement of alkanoic 
acid iontophoretic permeation was observed in nude rat as 
compared to furry rat (DelTerzo et a~., 1989). 
Skin blood perfusion also influences drug flux. 
Epinephrine decreased the lidocaine flux due to 
vasoconstricting effects, and conversely, tolazoline increased 
the drug flux (Riviere et a~., 1991; Riviere and Monteiro-
Riviere, 1991) . 
1.7 Mechanism of Iontophoresis 
The transport of a drug across stratum corneum may be 
transcellular (through the cells), or paracellular {around the 
cells), or by shunt pathway, or a combination of the above 
(Cullander, 1992). Accumulated clinical evidence suggests that 
the transport of ions occurs at least in part through a porous 
shunt pathway. This was demonstrated by the DC iontophoresis 
of a positively charged dye methylene blue, across excised 
human and mouse skin {Burnette and Marreo, 1986). The dye 
appeared on the excised skin in a dot like pattern and was 
observed on the receptor cell. Identification of the shunt 
routes for fluorescein dye was demonstrated with a pair of 
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scanning glass electrodes. When the micro-electrodes were 
moved across the localized dye, maximum voltage change was 
detected at the shunt region (Burnette and Ongpiattanakul, 
198 8) • 
In contrast, the transport of neutral molecules is not by 
direct electrostatic repulsion, but by current induced 
convective flow (Pikal and Shah, 1990a; Pika! and Shah, 
1990b) • Convective flow develops because the skin is 
negatively charged at physiological pH. As a result, the 
positive ions traverse through the skin to a greater extent 
than the negative ions. This sets up a net convective flow in 
the direction of positive ion transport. Thus, any solute that 
is present in convective flow will be transported across the 
skin. 
The mechanism of iontophoretic delivery is complicated. 
Several mathematical models provide an insight into the 
factors governing iontophoresis. Applications of classical 
models have been reviewed by Burnette (1989) and Kasting and 
Keister (1989) . A more recent membrane transport models is the 
Nerst Plank Diffusion Model (Kasting, 1992) . The equation that 
describes this model has three components: a diffusion 
component• an iontophoretic component•• and an electo-osmotic 
component•...... Symbolically, it can be written as: 
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J = Cu~ .. _ D{dc/dx}~+ D{zEFC/kT} •••••••••••••••. • Equation (3) 
where: 
J = molar flux, C = molar concentration, u = convective water 
flow, D = diffusivity coefficient, dc/dx = molar concentration 
gradient, z =ionic valence, E =electric field, F =Faraday's 
constant, k =Boltzmann's constant, T = temperature. 
The contribution of the convective flux to the overall 
transport is about 5% of the total iontophoretic flux for a 
solute with a transport number of about 0. 2 (Yoshida and 
Roberts, 1992) . The extent to which convective flux affects 
the transport of different solutes remains unclear. As this 
flow is directly dependent on the movement of the charged 
ions, convective flow will also increase with increasing 
current density (Burnette and Marrec, 1986). The theoretical 
analysis and initial experimental work by Pikal and Shah 
(1990a, 1990b) provide some additional insights. It is 
apparent from their analysis that; {1) the volume flow across 
the skin is independent of the induced osmotic effect; and (2) 
pore heterogenicity complicates the modelling of the volume 
flow effect, and its impact on the transport of different 
solute structures. In a separate study by Volpato et a~. 
(1995) acyclovir delivery by electro-osmosis was found 
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significantly higher than the iontophoretic delivery. 
1.8 Skin Effects 
Passage of electric current through skin can provoke 
sensation ranging from tingling, itching, slight pricking to 
erythema. When lidocaine was delivered from a 4% aqueous 
solution of its hydrochloride salt over a range of currents 
(0.13-0.4 A/cm2 ) for period of 10, 40 and 100 mins, various 
degrees of erythema were observed (Monteiro-Riviera, 1990) . 
Erythema in the drug-delivery-anode typically disappeared by 
24 hrs and was minimum under the cathode (Monteiro-Riviera, 
1990). A macromolecular capillary leakage as observed by FITC-
dextran fluorescence, and histological demonstration of 
extravasated white blood cells are shown to be caused by DC 
current of 5, 20, and 50 ~, or an AC of strength 20 ~ in 
hamster, chick and rabbit tibia (Nannmark et al., 1985). In a 
study by Rootman et al. (1988) iontophoresis (0.8 mA, 10 mins) 
in rabbit eyes was accompanied by reversible corneal 
epithelial edema with a small amount of mucosal discharge. 
Histological examination of the eyes showed circumscribed 
lesions. General irritation is the common side effect of 
iontophoresis (Ledger, 1992) and it is caused by electrical 
polarization due to continuous direct current. The possible 
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solution is the use of pulse or DC reverse current (Tapper, 
1981) . Electrical shocks experienced by some human volunteers 
were caused by high current density at the skin surface, which 
is avoided by increasing current strength gradually from zero 
to the desired value consistent with the patient compliance. 
Tapper (1979, 1981) has suggested that the use of thick 
pad/gauge (>3 mm.) beneath the negative electrode and the 
adherence to current-time limitation could help to avoid most 
of the iontophoretic burns (Tapper, 1979; (Ledger, 1992}. 
Isolated cases of contact sensitization to ketoprofen and 
components of the electrodes were also reported by Teyssandier 
et al. (1977). 
Despite the side effects of iontophoresis, the system 
when used properly can be extremely useful. Since parameters 
such as electrode-skin-contact area, current strength, the 
duration of current application (Prausnitz, 1996) and skin 
variation can affect the tolerability of a system (Ledger, 
1992; Molitor and Fernandez, 1939), no in vitro methodology 
exists to assess these parameters. By experimental trials, a 
current strength of 0.5 mA can be safely applied to skin of 
electrode-skin contact area of less than 10 cm2 (Sanderson et 
al., 1989) . 
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1.9 Op~zation of the Iontophoretic Transport 
With respect to patient comfort, the iontophoretic 
transport can be regulated by varying the applied current 
density and the area of application. The pH and the ionic 
strength of the drug solution, and the current amplitude and 
frequency of pulsed current can be optimized by response 
surface method to ensure the maximum iontophoretic delivery 
(Huang et al., 1996a; 1996b). Also, an electrode of choice 
should prevent the pH drift during iontophoresis which 
otherwise may decrease the solubility of the compound. 
Selection of extraneous ions should be limited to ions with 
least mobility and conductivity. Constant reversing DC current 
or pulsed current should be used to minimize skin burns. 
Vasoactive chemicals (vasoconstrictors like epinephrine and 
vasodilators like tolazoline) may be used to facilitate either 
a local or a systemic delivery of ionic compounds. 
1.10 Therapeutic App1ications of Iontophoresis 
Iontophoresis of different classes of drug have been 
therapeutically used under different conditions: dentistry and 
oral conditions (Gangrosa et al., 1980), dermatology (Singh 
and Roberts, 1993; Glass et al., 1980) ophthalmology (Peggy et 
al., 1985; Grossaman and Lee, 1989; Rootmans et al., 1988), 
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otolaryngology (Rigano et a~., 1992) and in miscellaneous 
conditions such as: hyperhidrosis (Holzle and Alberti, 1987}; 
in the diagnosis of cystic fibrosis (GLbson eta~., 1975); and 
intra-nasal dysfunctions (Weir, 1967). The iontophoresis of 
vinblastine in HIV-1 infected patients intolerant to systemic 
vinblastine in the management of cutaneous carcinoma widely 
improved the patient compliance {Smith et a~., 1992). 
1.11 Iontophoresis and Penetration Enhancers 
The use of chemical penetration enhancers with 
iontophoresis as to increase the transdermal delivery of high 
molecular weight polypeptides is suggested. Ethanol 
pretreatment of human skin was found to enhance insulin 
transport by a factor of 22 when compared to controls 
(Srinivasan et a~., 1990). Use of epidermal enzymes such as 
phospholipase-C significantly enhanced the permeation of 
mannitol and testosterone across skin {Patil et al., 1996). 
These observations suggest that it may be possible to use 
penetration enhancers and achieve therapeutic levels at low 
current strength. Such a synergistic effect was also 
demonstrated for leuprolide and cholescystokinn-8-analogs 
(Srinivasan et al., 1990). However, the combination of 
iontophoresis and penetration enhancers did not increase the 
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permeability of Sotalol (Hirvonen et al., 1993). It is likely 
that the combination of iontophoresis and chemical penetration 
enhancer are effective in improving iontophoretic delivery of 
large molecular weight compounds as compared to small 
molecules. The use of proteolytic enzyme inhibitors such as 
camostat mesylate and aprotinin as absorption enhancers in 
iontophoretic delivery of peptides have been observed to 
facilitate the delivery of vasopressin (Morimoto et al., 
1992a) and salmon calcitonin (Morimoto et al., 1992b) in rats. 
1 . 12 Iontophoretic Units/Device 
Most of conventional iontophoretic system use a steady 
direct current in which the active electrode is incorporated 
in a moist pad or gauze in direct contact with the skin 
(Stillwell, 1971) . In some cases, the indifferent electrode is 
larger than the active electrode and is placed at any 
convenient position on the body. This position does not 
significantly effect the iontophoretic flux (Lekas, 1979). 
Three types of iontophoretic devices are commercially 
available: line operated devices (used in the device to 
diagnose cystic fibrosis), simple battery operated units 
(Phoreso~ from Motion Controls Utah; Drioni~ an FDA approved 
device from General Medical Co LA) and rechargeable power 
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sources (HidreXC from Gesellschaft fur Medizin and Technik, 
Wuppertal, Germany) (Tyle and Kari, 1988). 
1.13 Limitation of Iontophoresis 
The iontophoretic delivery device is costly because of 
the electrodes, the electronic circuit, and the number of 
batteries required to sustain a therapeutic delivery rate. The 
possibility of unwanted effects of iontophoresis and drug on 
skin have been mentioned in literature but not adequately 
researched. 
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1.14 Rationale and Specific Research Objectives 
One way of treating causalgia is to interfere with the 
activity of sympathetic efferents that activate sensory 
afferents in the periphery. Alternately, beneficial effects 
might be expected if one could block the alteration in the 
central processing that leads to the abnormal pattern of the 
sympathetic outflow. Unfortunately, the nature of central 
processing is only now receiving more attention, and presently 
little information is available in literature as to its 
mechanism. 
Whereas, the intrathecal administration of adrenergic 
agonists such as epinephrine produce antinociception in a rat 
model of causalgia, intravenous phentolamine {non-specific 
alpha adrenoreceptor antagonist) produces clinical pain relief 
in humans (Raja et al., 1991). These results indicate that a 
adrenergic receptors are located in the periphery and not in 
the spinal cord. Also, these results are consistent with the 
human studies (Campbell et al., 1988, 1992, Treede et al., 
1992, Abram and Lightfoot, 1992), suggesting that the main 
abnormality in causalgia is in the expression of a 1 receptors 
on the primary afferent fibers. 
The present administration of alpha adrenoreceptor 
antagonists involve the invasive routes. This may result in 
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infection, damage to the wound, and even trauma. Since, 
iontophoresis is a noninvasive drug delivery system it reduces 
these unwanted effects. Iontophoresis shares the advantages of 
transdermal delivery, which include the bypass of hepatic 
first pass effect, gastrointestinal vagaries and controlled 
plasma level of potent drugs. The peaks and troughs associated 
with conventional dosage forms can be accurately controlled 
and titrated over time by employing iontophoresis. The inter-
and intra subject variability is considerably reduced as the 
rate of delivery is proportional to the applied current 
(DelTerzo, 1989) . 
By definition, an a 1 adrenergic receptor antagonist when 
delivered distal to the site of injury in the appropriate dose 
{obtained from dose response curve) by transdermal 
iontophoresis will provide pain relief. 
Controlled delivery can be achieved by altering the 
strength of the current, the duration of iontophoretic 
delivery, or both. Its advantage in treating a local condition 
like causalgia lies in its potential to deliver drug in high 
concentration to its site of action with minimal systemic 
uptake. 
The ionic nature, high water solubility and a 1 receptor 
specificity make terazosin ideal for iontophoretic delivery in 
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the treatment of causalgia. To investigate this possibility, 
the following specific research objectives were undertaken: 
(1) To develop a sensitive method for the quantitative 
determination of terazosin in biological fluids. 
(2) To optimize the conditions for iontophoretic delivery and 
investigate the drug delivery in rat. 
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2. 0 DEVELOPMENT OF SAMPLE PREPARATION TECHNIQUE FOR TERAZOSIN 
AND PRAZOSIN BY SOLID PHASE EXTRACTION AND HPLC. 
2.1 Terazosin Hydrochloride (Martindale, 1993) 
CAS: 63590-64-7b (terazosin); 63074-0(terazosin hydrochloride, 
anhydrous); 70024-40-7 (terazosin hydrochloride, dihydrate); 
1-(4-amino-6,7,dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-
furanyl)carbonyl-1] piperazine hydrochloride dihydrate 
Source: Abbot Labs, Montreal, Canada; Lot no 88615-AC-00 
NH2 .HCL. 
Figure 2.1 Chemical Structure of Terazosin Hydroch~oride 
2.1.1 General Description 
A white to off-white odourless powder, freely soluble in 
water and in methanol; mp, 272.6-274°C; pKa, 7.1 (proton 
gained) . Terazosin exists as racemic mixture and both forms 
are pharmacologically active (Kyncl, 1986) . 
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2.1.2 Pharmacoki.netics, Metabo~ism and Stability (Titmarsh and 
Monk, 1987) 
Terazosin 
rapidly and 
is a specific cx1 receptor blocker and is 
almost completely absorbed from the 
gastrointestinal tract after oral administration 
(bioavailability is 90%). The drug is metabolized in liver and 
one of its metabolites has antihypertensive activity. 
Terazosin is 90 to 94% bound to plasma protein. It is 
chemically related to prazosin, but with a longer duration of 
action. After oral administration in rat, terazosin reaches 
em~ in about 3 hrs and has an elimination half life of 2.3 
hours. In normal humans, the elimination half life is 
approximately 12 hours. 
In solid state, TRZ is relatively stable under high 
thermal stress and photochemical degradation. However, TRZ 
rapidly degrades in a weakly acidic and basic solutions at 
elevated temperature (Chang and Bauer, 1991) . 
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2.2 Prazosin Hydrochloride (Martindale, 1993) 
CAS-19216-56-9 (prazosin); 19237-4-4 (prazosin hydrochloride), 
l-(4-amino,6,7-dimethoxy-2-quinzolinyl)-4-2-furoyl) piperazine 
monohydrochloride 
Source: Sigma Chemicals, StLouis, MO, USA; Lot no 13H0197. 
CH30 
Figure 2.2 Chemical Structure of Prazosin Hydrochloride 
(Ct9H21N50 4 • HCL = 419.9) 
2.2.1 General Description (Koster, 1989) 
A white to tan colored, odorless or almost odorless 
powder. Very slightly soluble in water and in alcohol, 
slightly soluble in methyl alcohol and in dimethylformamide; 
practically insoluble in chloroform. and acetone. Prazosin 
exists in various polymorph (a,~,y) for.ms. The alpha form can 
be reproducibly manufactured. It is superior to the other 
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poly.morphs due to ease of handling, storage, stability and 
formulation. The alpha form is used clinically. The drug is 
sensitive to light and must be stored in amber colored vials. 
2.2.2 Pharmacokinetics, Metabolism and Stability (Koster, 
1989) 
Prazosin is readily absorbed from gastrointestinal tract. 
After oral absorption, the peak plasma concentration is 
reached in 1 to 3 hours. The oral bioavailability is variable, 
ranging from 43 to 58%. Prazosin is 92% bound to plasma 
proteins. Prazosin is extensively metabolized in liver and 
some metabolites have hypotensive activity. Excretion of the 
metabolites and unchanged prazosin is mainly through the 
feces. The elimination half life in normal humans is 3. 9 
hours. 
2.3 Deve1opment of the HPLC Technique for Terazosin 
Previous methods of measurement of prazosin and terazosin 
in biological fluids are based on spectrophotometry (Wood et 
al., 1976) and high performance liquid chromatography with UV 
(Paterson, 1984) and fluorescence (Bhamra et al., 1986) 
detection. The HPLC analytical technique for TRZ used in our 
research was adapted from Bhamra et al. (1986). Due to delay 
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in elution time and peak tailing of TRZ and PRZ, the above 
method {column: Spherisorb SSW silica (25 x 0.5 em); mobile 
phase: 10 mM of ammonium perchlorate in methanolic solution at 
a flow rate of 2.0 mL/min} was altered to Lffiprove the desired 
resolution and sensitivity. 
NOVA-P~ C18 column was used. The mobile phase consisted 
of 0.1 M phosphate buffer (pH 7.0), CH3CN and THF in a volume 
ratios of 76:18:6. At a mobile phase flow rate of 1 mL/min, 
terazosin and prazosin showed good fluorescence. The peaks 
were sharp and completely resolved from one another. The 
standard elution t~e of TRZ and PRZ was 3.2 ± 0.3 and 5.8 ± 
0.5 min respectively. 
Detection of the compounds were done either by UV (245 
nm) or by fluorescence method (ex 375 nm, em 400 nm) . The 
assay sensitivity by the fluorescence method was 0.05 ng/mL as 
compared to 45 ng/rnL for the UV method at a signal to a noise 
ratio of 6. Due to marked difference in the sensitivity of 
the two detection methods, the UV procedure was qualified to 
in vitro studies while the fluorescence method was primarily 
used for in vivo study. Additionally, fluorescence detection 
reduces analytical interferences from other plasma substances. 
The traditional TRZ extraction technique from plasma 
involve liquid - liquid extraction (Paterson, 1984; Bhamra et 
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al., 1986). These methods require large sample size and 
involve lengthy extraction procedures. Al terna ti vely, we 
developed a solid phase extraction (SPE) technique for TRZ and 
PRZ as described in the section 2.7 (Singh et al., 1996). The 
SPE procedure is preferred over traditional extraction 
techniques with regards to time, labor, efficiency of 
extraction, high drug recovery and assay reproducibility 
{Krishnan and Abraham, 1994). The high recovery enables the 
quantification of small amount of drug. Furthermore, the SPE 
technique uses relatively small amount of organic solvent 
making the process environmentally friendly. By integrating 
SPE with HPLC, complete automation of the sample analysis can 
be achieved. 
2. 4 Introduction to Solid Phase Extraction (Blevin et al., 
1993) 
Solid phase extraction is a physical process of 
separation of drug from unwanted matrix involving a liquid and 
a solid phase. The principle of separation is similar to HPLC. 
In SPE, the solid phase has a preferential attraction to the 
solid sorbent than to the solvent in which the isolate is 
dissolved. As the sample solution passes through the sorbent 
bed, the isolate gets bound to the sorbent, while the unwanted 
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sample components pass through. A very selective extraction 
resulting in a highly purified concentrated isolate can be 
achieved by choosing a suitable sorbent. Retention of the 
isolate depends upon the physio-chemical properties of both 
the sorbent and the isolate. 
Bonded silica has gained popularity as a sorbent due to 
its versatility and availability with a wide range of physio-
chemical properties. Organosilanes (R) are attached to the 
silica substrate (-Si-0-) through a silyl ether linkage. The 
sorbent will have different physio-chemical properties 
depending on the functional group R. Bonded silica are stable 
at pH range of 2 to 7.5. Above pH 7.5, the silica substrate is 
susceptible to dissolution in aqueous solution. Below pH 2.0, 
the silyl ether linkage is labile and the functional groups on 
the surface will begin to cleave changing the sorptive 
properties nonreproducibly. 
Solvation of sorbent is necessary for sorbent to interact 
reproducibly with isolates. In effect, solvation is the 
wetting of the sorbent creating an environment suitable for 
isolate retention. This is achieved by passing large volumes 
of polar solvents like methanol, acetonitrile, or isopropanol. 
Once solvated, the sorbent bed should not be allowed to dry 
before application of test sample. A£ter passing the test 
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sample through the sorbent bed, the bed is drained to discard 
unwanted interfering substances. Subsequently, the sorbent is 
washed with a suitable solvent to selectively remove all other 
adhering interfering substances before the final elution of 
the analyte with an another solvent. 
2.5 Selection of Solid Phase Extraction Columns 
There are two different approaches for extracting analyte 
from the test sample. In the first method, the sorbent has a 
higher affinity for the analyte to retain it, and at the same 
time allowing the unwanted components of the sample to pass 
through. In the second method, the SPE sorbent has a lower 
affinity for the analyte allowing it to pass, while retaining 
the unwanted components. In the former approach, the analyte 
is finally eluted with a suitable eluent, while in the latter 
no final elution is necessary. 
The selective retention of the drug or the extraneous 
matter depends upon the nature of sorbent. It is also based 
upon the functional group present on the analyte and 
composition of the sample matrix. Each sorbent within a given 
extraction mechanism exhibit a unique property of retention 
and selectivity which may be quite specific for the isolate. 
If an extraction involves a nonpolar mechanism, it may be 
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necessary to test several sorbents within a given category to 
find optimum balance between high recovery and good clean up 
(little or no plasma contaminants in the eluant). For TRZ 
(pf<a = 7 .1), a hydrophilic and water soluble compound with an 
amino functional group, the cyanopropyl sorbent column due to 
its intermediate polarity proved a good choice. The 
interaction of CN-sorbent in a polar environment is due to 
hydrophobicity as well as the polar characteristics of silica 
and residual silanols (cr. Krishnan and Abraham, 1994). 
2.6 Bond E1ut~o1umns (Varian Sample Preparation literature ) 
Bond Elut® cyanopropyl cylindrical columns are made of 
polypropylene reservoir containing 50 mg to 10 g of sorbent. 
Smaller cartridges are useful when sample size is very small, 
or when very small volume is needed for maximizing drug 
concentration. The maximum drug retention capacity is about 5% 
of the sorbent mass. 
2.7 Solid Phase Extraction of Terazosin and Prazosin 
2.7.1 Materia1s and Methods 
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Prazosin was used as an internal standard for terazosin. 
Deionized water was obtained using Barnstead Nanopure II 
system (Barnstead, MA, USA) . All other solvents and reagents 
were of HPLC and analytical grade. Human plasma from healthy 
volunteers was used for the preparation of calibration curve 
and validation of the analytical procedure. Cyanopropyl bonded 
silica SPE cartridges (Bond Elut®, 100 mg, lmL) were obtained 
from Varian Sample Preparation Products, CA, USA. 
2.7.2 Preparation of Standard Solutions 
Stock solutions of TRZ (equivalent to 0. 4 mg/mL of 
terazosin base} was prepared in water and diluted to obtain 
five different standard solutions ranging from 10 to 320 
ng/mL. Prazosin solution (equivalent to 5 ~g/mL of prazosin 
base) was prepared in 10% methanolic solution for use as 
internal standard and stored in amber colored vials. 
2.7.3 Sample Preparation and Extraction 
Plasma samples 
spiked with 50 J.lL 
( 0. 5 mL each in five test tubes) were 
of a standard solution of known TRZ 
concentration and 20 J.lL PRZ solution, as internal standard. A 
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sixth plasma sample (blank) contained only SO ~L of water and 
20 ~L PRZ solution. The samples were further diluted with 1 mL 
0.1 M phosphate buffer (pH 7.0) and mixed with the aid of a 
vortex mixer. The samples were then allowed to stand while the 
SPE columns were being conditioned. The SPE columns were 
mounted on sample preparation manifold (Adsorbex®, E Merck, 
Darmstadt, FRG} and conditioned by treating sequentially, with 
1 mL methanol, followed by 1 mL of buffer solution, taking 
care not to let the column go dry. Diluted plasma samples were 
added to the conditioned SPE columns and allowed to percolate 
slowly under reduced pressure. A£ter air-drying the column for 
three minutes the columns were washed with two, l mL portions 
of buffer solution, with 1 minute intermittent drying. Then 
the analytes were extracted with two, 1 mL portions of 
extraction solution consisting of THF and CH3CN in the 
respective volume ratio of 1:3. The eluate was evaporated to 
dryness with the aid of thermostated water bath (37 °C} and a 
stream of nitrogen gas. The residue was reconstituted in 200 
~L of mobile phase. Twenty J.i.L of reconstituted sample was 
injected into the HPLC system. The PHR of TRZ to PRZ were 
measured and plotted against the spiked TRZ concentrations. 
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2.7.4 Chromatographic System 
The HPLC system comprised a Waters Model 510 solvent 
delivery system (Waters Associates, MA, USA), Shimadzu SIL 9A 
autoinjector and fluorescence detector (Shimadzu Corporation, 
Kyoto, Japan), set at an excitation wave length 345 nm and an 
emission wave length of 400 nm. The analytical column was a 5 
x 10 mm cartridge packed with Nova-PaJC5 C18 reverse phase 
particles (Waters Associates, MA, USA) fitted with a C18 guard 
column. Responses were recorded as peaks of a recorder (Kipp 
& Zonzn, Delft, Holland) which was operated at speed of 10 
mm/min. The composition of mobile phase was adapted from the 
work of Paterson (1984) and modified to suit our 
instrumentation set up. It consisted of 0.1 M phosphate buffer 
(pH 7.0), CH3CN and THF, in the respective volume ratio of 
76:18:6 which provided the desired resolution and sensitivity 
of TRZ and PRZ. Mobile phase was clarified by filtering 
through 0.45 ~membrane filter (Millipore Corporation, Mass, 
USA), degassed by purging helium and was delivered 
isocratically (room temperature) at a flow rate of 1.0 mL/min. 
2.7.5 Method Precision 
Precision of the analytical procedure was evaluated by 
determining the linearity of response over 10-320 ng/ml drug 
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concentration, assay detection limit, percentage drug recovery 
and procedure reproducibility. 
2.7.6 Linearity 
Standard calibration curve of PHR versus concentration of 
spiked standard solution of TRZ was assessed by the 
coefficient of determination obtained by linear regression 
analysis. The process was repeated on five separate occasions 
and the reproducibility was determined by measuring the 
coefficient of variation of the slopes of the curves. 
2.7.7 Reproducibility of Procedure 
Precision of the extraction method was determined by 
replicate analysis of plasma samples spiked with three 
concentrations (54, 100, 200 ng/mL) of TRZ. Multiple number of 
samples (half mL each) of these three test solutions were 
prepared on the same day and stored at -20 °C and analyzed 
periodically. Inter-day comparison was based on analyses, 
performed in duplicates, on five different days, over a 
period of fifteen days. Intra-day comparison was based on four 
determinations of the three test solutions performed on one 
day. Mean, coefficient of variations and F values for two-way 
ANOVA studies were calculated. 
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2.7.8 Reuse of the SPE Columns 
Generally, the SPE columns are meant for single use and 
the manufacturer does not recommend its repeated use. However, 
we have explored the possibility of reusing the SPE columns 
for repeated use. The column was reconditioned as follows: 
immediately after extraction, 1 x 1 mL of methanol was passed 
through the cartridge, followed sequentially (with drying in 
between the steps) with 3 x 1 mL dichloromethane, 3 x 1 mL of 
water and finally, 1 x 1 mL of methanol. Till further use, the 
columns were stored in a closed container. 
2. 7. 9 Application to the Pharmacokinetics of TRZ in Rat 
The analytical procedure was used to study the 
pharmacokinetics of TRZ in rat. A male Sprague Dawley rat 
(Charles River, St Constant, Canada) weighing 473 g, was 
anaesthetized using 4% halothane and its jugular vein was 
cannulated with a 1 mm diameter polyethylene catheter, fitted 
with a three-way valve. This facilitated multiple blood 
sampling for drug analyses. Patency of the catheter was 
maintained with intermittent flushing with heparinized (10 
units/mL) sodium chloride injection (0.9% NaCl, Astra Canada 
Inc, Mississauga, Canada) . An intraperitoneal dose ( 0. 33 
mg/kg) of TRZ was injected. Blood samples (0.5 mL) were 
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removed via the catheter before the drug administration and at 
fixed time intervals over four hours during which period the 
rat was maintained in anaesthetized state using 1.5% 
halothane. Blood samples collected in heparinized 
polypropylene tubes were centrifuged immediately to obtain 
plasma which were stored at -20 oc until analysis. Before 
analysis, the plasma samples were allowed to thaw at room 
temperature and were extracted along with spiked standard TRZ 
in plasma and analyzed by the HPLC procedure described above. 
2.7.10 Data Ana1yses 
Calibration curves of PHR versus spiked concentration of 
TRZ were analyzed by linear regression analysis to obtain the 
equation of best fit. Inter-day variation in the analytical 
precision were assessed by using two-way ANOVA regression 
model with a significance level of p = 0.05. Intra-day 
comparisons were done by Student-t test and by calculating 
coefficient of variations. Concentration-time data following 
intra-peritoneal dose of TRZ was fitted with the help of a 
RSTRIP computer stripping program (Micromath Scientific 
Software, Utah, USA) . 
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Figure 2. 3 Calibration Curve: Assay Validati.on. 
A plot of PHR versus concentration of spiked standard 
solutions of TRZ. Each point represents the mean ± Sd of five 
determinations. 
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Tabl.e 2.1 cal.ibration Data: Assay Validation Studies (n = 5) • 
Cone. PHR PHR PHR PHR PHR 
ng/mL dl d2 d3 d4 d5 
10.14 0.105 0.099 0.085 0.205 0.110 
40.56 0.429 0.424 0.360 0.508 0.422 
81.14 0.873 0.821 0.768 0.943 0.836 
162.83 1.655 1.586 1.576 1.720 1.720 
324.56 3.382 3.243 2.873 3.22 3.275 
EQUATIONS OF CALIBRATION CURVES ON DIFFERENT WORKDAYS R_2 
1 PHR = 0.00207.CONC + 0.005299 1.00 
2 PHR = 0.01980.CONC + 0.004267 1.00 
3 PHR = 0.01782.CONC + 0.00298 9.99 
4 PHR = 0.0191.CONC + 0.136 9.99 
5 PHR = 0.0202,CONC + 0.230 9.99 
CV SLOPE (m) (n = 5) = 5.79% 
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Tabl.e 2.2 Assay Validation: Interday and Intraday Variation. 
Number of samples of each concentration (54, 100, 200 nq/mL) 
of TRZ were prepared and treated as unknowns. 
Spiked amount 
of TRZ (ng/mL) 54 100 200 
Inter-day variation (individual values, nq/mL)) 
Day 1 52.22, 54.92 91.46, 96.46 190.18, 186.22 
Day 4 56. 50, 53.94 98.44, 92.10 205.84, 200.72 
Day 7 56. 02, 56.14 104.32, 104.26 204.88, 202.66 
Day 11 53.40, 54.76 98.00, 95.60 201.58, 201.46, 
Day 15 53.42, 53.86 98.80, 98.22 206.60, 197.12 
Mean. 54.52 ± 1.40 97.77 ± 4.28 199.73 ± 6.73 
± SD(n = 10) 
% cv (n = 10) 2.57 4.38 3.37 
Two-way 
AN OVA F value 0.22 0.22 7.07 
Intra-day variation {individual values, nq/mL) 
All 
samples 53.42, 53.86 98.80, 98.22 206.60, 197.12 
analyzed 52. 62, 51.96 103.26, 99.40 210.40, 204.94 
On day 15 
Mean 52.97 ± 0.84 99.92 ± 2.28 204.76 ± 5.59 
± SD (n = 4) 
%CV 1.59 2.29 2.73 
(n=4) 
t-value 2.44 0.07 1.70 
Critical F-value (0.05, df, 4) = 7.71, Critical t-value (p = 
0.025; df 3) = 3.1 
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2.8 Result and Discussion 
2 • 8 . 1 Li.neari ty, Recovery, Detection Limi. t and Reproduc.ibili ty 
PHR obtained with human plasma samples spiked with the 
five different concentrations of TRZ over the concentration 
range of 10 to 324 ng/mL were linearly related to the spiked 
concentrations (Table 2.1). The equation of best fit for the 
line (average of five determinations) was: 
Y = 1 • 9 6 X 1 o-2 X + 3 • 9 5 X 1 o-2 
where Y is the peak height ratio of TRZ peak to internal 
standard peak and X is the spiked TRZ concentration (Figure 
2.3). Coefficient of determination obtained with the replicate 
determinations ranged from 99.7 -100 %and the coefficient of 
variation (CV) of the slope determined on the five separate 
occasions was 5.79% (Table 2.1). 
The SPE procedure was very efficient. The extraction 
procedure developed using cyanopropyl column selectively 
retained only TRZ and PRZ, leaving out minimum interfering 
substances as evident from negligible residue left in the test 
tube after evaporation of extraction fluid. The recovery of 
TRZ from plasma matrix by this procedure was virtually 
complete (range 100-104%) (Table 2.3). Complete extraction will 
enable one to quantify low drug concentrations from small test 
samples of 0.5 mL or less. The SPE procedure was also 
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Tabla 2.3 Recovery (~)of TRZ from plasma matrix was determined by comparing the PHR of 
the extracted plasma samples containing known amount of analytes with those obtained by 
direct injection of standard solution without any treatment. The extraction efficiency 
is ratio of PES/PUS* expressed in percentage. 
Concentration 
(ng/mL) 
Work 
Day 
*~%=(PER /PUS)xlOO 
I~% 
---------------~------~-----------~-----------~-----~-----~----~-----~-----~--~-~~---~--
10.14 
162.28 
* 
1 
5 
1 
5 
~% = efficiency in percentage. 
0.1003/0.09786 - 102.5% 
0.1002/0.09724 = 103% 
1.628/1.6443; 101% 
1.557/1.5725 = 101% 
PES = peak height ratio (TRZ/PRZ) of extracted sample 
PUS = peak height ratio (TRZ/PRZ) of unextracted sample 
I~ = first extraction; II~ = second extraction 
0.0853/0.0927 - 92% 
1.553/1.6421 = 94.5% 
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efficient with regard to time, labor and economy of organic 
solvent needed for extraction. With the use of a vacuum 
manifold 12 samples could be extracted in about 10 minutes. 
Only 2 mL of organic solvent was necessary for an extraction. 
Minimizing organic solvent waste made the SPE procedure 
environmentally friendly. The detection limit for TRZ in 
plasma was found to be 0. OS ng/mL, with a signal-to-noise 
ratio of 6 at an attenuation range 16 (i.e., the ratio of the 
output to recorder terminal was 16) . This detection limit is 
an improvement over 0.25 nq/mL sensitivity reported by 
Peterson (1984) . However, TRZ can easily be detected at a much 
lower concentration at three times the noise level. 
The reproducibility of the 
determined by both intra-day 
analytical procedure was 
and inter-day variability 
studies. The % CV for the inter-day variability were 2.57, 
4.38, and 3.37 respectively, for the spiked TRZ concentration 
of 54, 100 and 200 ng/mL (Table 2.2). Analysis of variance 
using two-way ANOVA regression model showed no significant 
difference (p > 0.05) between determinations performed from 
day-to-day over 15 days. The intra-day %CV (n = 4) for three 
test samples were 1.59, 2.28 and 2.73 respectively. 
Performance of t-test (p = 0.025, df 3) on intra-day 
measurements showed no significant variations. 
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Figure 2.4 TRZ and PRZ HPLC Chromatograms (assay validation) : Figure (a) represents 
chromatogram of blank human plasma spiked with internal standard. Figure (b) represents 
the chromatogram of human plasma spiked with 5 ng of TRZ and 100 ng of PRZ. PRZ is 
structurally related to TRZ which Jnakes it a good internal standard. The retention times 
of standard TRZ and PRZ were 3.2 ± 0.2 (n > 100) and 5.7 ± 0.4 (n > 100) minutes 
respectively. Figure (c) is the chromatogram of an inrat sample (spiked with internal 
standard) two hours after intra-peritoneal administration of 0.33 mg/kg of TRZ. The 
injection volume for all samples were same. Rat plasma sample (c) was analyzed at a 
higher sensitivity as to enable the accurate determination of peak height ratio. 
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Figure 2.5 RSTRIP Simu1ation of TRZ Plasma Concentration-Time 
Profile After Single ip dose in a Rat. The values • shown are 
the experimentally determined concentrations after an ip 
dose of 0.33 mg/Kg of TRZ in a rat. The line drawn is the 
best fit line as determined by the RSTRIP program. 
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The results also indicate that TRZ in plasma stored at -20 oc 
remained stable over at least 15 days and all nonbiological 
samples were stable at 5 °C for at least 3 months. 
2.8.2 Pharmacokinetics 
Terazosin plasma concentration-time profile after a 
single 0.33 mg/kg intra-peritoneal dose of TRZ is shown in 
Figure 2.5. The dose was selected based on literature data in 
the study of effects of TRZ in rats (Kyncl, 1986) . The RSTRIP 
program chose biexponential fitting as the most suitable model 
and calculated certain pharmacokinetic parameters which are 
listed below: 
elimination rates: k1 = 0. 0036 hr-1 , k2 = 0. 0466 hr-1 ; Are a 
under the concentration time curve(AUC) 0_ = 10729 ng.min/mL 
Peak concentration (~ = 31.0 ng/mL) attained at 59.6 minutes 
('tmax) • Assuming complete absorption from the ip dose, the 
volume of distribution (1.17 L/Kg) was calculated from: 
Vd = (AUMC x Dose) / (AUC x AUC) ............. (Gibaldi and 
Perrier, 1982). 
Taking the slowest of the two rates as the elimination 
rate, the elimination half life was calculated to be 3.2 
hours, compared to the reported half life of 2.3 hours after 
oral administration in rats (Chang and Bauer, 1992) . 
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2.9 Conc1usions 
The SPE of TRZ from plasma and its HPLC quantification 
with fluorescence detection was found to be sensitive, 
precise, reproducible and efficient. The method can be easily 
adapted to monitor TRZ concentration in patients. 
3.0 Transder.ma1 Iontophoresis of Terazosin in Rats 
3. 1 Introduction 
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Human skin consists of a highly vascular dermis, about 
1000 ~ thick, and an avascular epidermis of about 100 ~ 
thickness. The epidermis can further be divided into three 
distinct layers consisting of the innermost basal layer, the 
intermediate granular layer, and the outermost layer the 
stratum corneum. It is generally agreed that the impermeable 
nature of the skin is primarily due to stratum corneum, which 
is about 10 ~ thick. Cullander (1992) has described stratum 
corneum as a protein rich corneocytes "bricks" surrounded by 
lipid rich "mortar." The intracellular mortar is composed of 
multicellular lipid bilayers. The lipid composition of the 
stratum corneum is unusual as it has large quantities of 
ceramides and free fatty acids. At normal body temperature 
these components are generally more ordered than other common 
membrane lipids. Therefore, the stratum corneum provides a 
greater barrier to the penetration of the substance than do 
other biological membrane such as the intestinal wall or the 
oral epithelium. Most of the lipids of the stratum corneum 
have order-disorder transition temperatures which are greater 
than the body temperature. In contrast, lipids of most cell 
membranes in the body generally have a transition temperature 
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less than the normal body temperature. Because of the unique 
structure and composition of the stratum corneum, lipophilic 
compounds tend to penetrate more readily than hydrophilic 
compounds in the presence of concentration gradient. However, 
under the influence of an electric field, ionic species can 
also penetrate the stratum corneum. Several investigators 
(Cullander, 1992; Burnette and Marrec, 1986) have identified 
hair follicles, sebaceous glands, and sweat glands as 
important routes (shunt pathways) of penetration for ionic 
compounds. Burnette and Marrec (1986) have shown that ionic 
dyes (eg., methylene blue) migrate through the skin via the 
pores identified as sweat and sebaceous glands. Using minute 
electrodes, Grimnes (1984) has found evidence of 
transappendageal migration of ions. While there is 
considerable evidence to support the ionic transport along the 
shunt pathway, migration of ionic species along the 
paracellular pathway cannot be ignored (Bodde eta~., 1989; 
Lee et al., 1996). Accumulated literature fails to point out 
the exact transport pathway of ionic moiety. One of the 
several explanations is the enormous variation in skin samples 
in different animal species. Additionally, no other animal 
species other than humans possess the eccrine gland over the 
general skin surface. An animal skin homologous of human skin 
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that is completely appropriate for iontophoretic studies does 
not exist. The next choice is the human cadaver skin. Even 
that poses difficulties, especially in the availability of 
fresh samples. 
Therefore, the bulk of research in this area depends 
upon the animal models. The animal model used are: hairless 
mouse (Durrheim et al., 1980), furry mouse (Behl and Barret, 
1980), hairless rat (Garcia et al., 1980), nude rat (DelTerzo 
et al., 1986), fuzzy rat (Behl et al., 1985), hairless guinea 
pig(Friedlander et al., 1988), rhesus monkey (Wester and 
Maibach, 1976) and mini pig (Ainsworth, 1960) . It has been 
found that in the passive diffusion studies, the hairless 
animals are far better models for simulating human skin than 
the furry animals (Behl et al., 1985}. It should also be noted 
that hairless rats are not without hair follicles. They have 
some residual follicles in the skin and perhaps it is this 
feature that makes it a good model for transdermal study 
(Friedlander et al., 1988}. Although some information is 
available about the nature of skin in passive drug transport, 
little is known about the animal skin for iontophoretic 
uptake. As evident from the contemporary literature both fuzzy 
and furry animals have been used (Siddiqui et al., 1987; 
DelTerzo et al., 1986). This lends support to the hypothesis 
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(Siddiqui and Chein, 1987; DelTerzo et al., 1989) that 
iontophoretic delivery is relatively independent of the source 
and the type of skin used. 
In the proceeding sections, transdermal iontophoresis of 
TRZ in in vitro and in in vivo conditions are described. The 
following drug delivery issues have been examined: (a) 
stability of TRZ and in vitro delivery (b) drug delivery in 
rat. In the in vitro study excised fuzzy rat skin was used 
while in in vivo study both the furry and fuzzy rats were 
used. 
3.2 Animals 
All experiments were conducted using 250-300 g Sprague 
Dawley Rat and 250-320 g Fuzzy Rats (Charles River Canada, St 
Constant, Canada) . ~nimals were housed in the Animal Care 
Facility, Memorial University of Newfoundland, at a room 
temperature of 22°C. A 12-hr light dark cycle (light 
switched on at 0700 hr) was maintained, and the animals had 
free access to the rat chow and tap water. All experiments 
were conducted by the guidelines of the Canadian Council of 
Animal Care and were approved by the Memorial University 
Animal Care Committee. 
3. 3 In Vitro Experiments 
3.3.1 Skin Preparation 
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Fuzzy rats were killed with an overdose of anesthetics 
(approximately 2 mL of 60% w/v urethane in saline) . Skin from 
the abdomen region was surgically removed according to the 
procedure of Durrheim et a~. (1980) and kept fresh over ice at 
0-4 °C (Swarbick et a~., 1982) for a maximum of one week. 
Before use, a piece of skin of approximately 1.5 cm2 surface 
area was cut from the excised skin and allowed to attain room 
temperature. It was then mounted on side - side diffusion 
cells (Figure 3.1) with the dermis facing the receptor cell. 
3.3.2 Experimental Set Up 
In vitro experiments were carried out in diffusion cells. 
The experimental set up consists of following parts: a 
constant current supply (1) and two electrodes that convert 
the electronic current to ionic current (2) • The donor cell 
contains the aqueous solution of the drug (S)and the receptor 
cell (6) contains the isotonic solution of sodium chloride. 
Magnetic stirrer (3) mixes the ionic moieties in the donor and 
the receptor cells. The cells were jacketed by circulating 
water and the temperature of the water was maintained at 37~C 
by a thermostat (Julabo Labortecknik, Germany) . Fresh 
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Figure 3.1 A Prototypical Glass Diffusion Cells. Volume of solution used is 3.0 mL. The 
electrode system was i~serted into their respective ports and care was taken to avoid 
the formation of air gap adjacent to the skin. 
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exercised skin (4) was sandwiched between the donor and the 
receptor cells (drug permeation area = 0. 7 cm2 ) • After the 
electrode activation, sampling from the donor solution was 
done for every hour for the first 8 hrs and then after 24 hrs. 
Equivolume of solution removed was replaced by normal saline. 
3.3.3 Stabi1ity of TRZ under Iontophoresis 
Test run for the chemical stability of TRZ was 
investigated under 5 min reversing DC current (0.25 mA; 0.7 
cm2 ) for 24 hours in glass diffusion cells using Pt/Pt 
electrodes. The drug solution (0.1% w/v) was placed in both 
the donor {5) and the receptor compartments (6) but without 
the sandwiched skin. The electrodes were placed at the 
respective ports at 5.5 em apart from each other. Samples were 
taken at regular time intervals and kept frozen at -20 °C till 
HPLC analysis. 
During the iontophoretic run, the color of the solution 
changed from colorless to reddish brown. This suggested a 
possible drug degradation, which was confirmed by the HPLC 
analysis of the solution. The chromatograms (Figure 3.3 (i a)) 
exhibited an extra peak before the TRZ peak. Modification of 
platinum electrodes was done by incorporating a salt bridge in 
the electrode assembly (integrated electrode) (Figure 3.2). 
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Repeating the above experiment with the integrated electrodes 
showed no color change in the drug solution. This was also 
confirmed from the HPLC analysis of the solution. The 
chromatograms exhibited no extra peak before the TRZ peak 
(Figure 3.3 (ib and iib)). 
Although, the chromatograms of the coloured solution show 
a single additional peak before the TRZ peak, multiple peaks 
were also seen in UV analysis. It may be possible to identify 
and isolate these compounds in future experiments, but in the 
present context, no such study was carried out. 
3.3.4 Preparation of the Integrated Electrode 
Agar grade-A (0.75 g) was dissolved in 25 mL of 0.9 % w/v 
sodium chloride solution and heated to boiling to give an 
agar-sodium-chloride gel. With the help of a 20 Gl112 needle 
(Becton Dickinson, NJ, USA) fitted to a 5 mL syringe, the hot 
gel (temp 70-75°C) was filled into a 2.5 mm diameter 6 inches 
long polyethylene tubing and allowed to cool. During cooling 
care was taken not to allow the entrapment of air. The tubing 
were then cut into equal sizes of length 2.5 am and wrapped in 
a parafilm (American Can Co, CT, USA) followed by aluminum 
foil. It was then stored at 0-4°C to prevent gel shrinkage and 
6S 
... r-------- Pt electrode 
skin 
Salt bridqe 
terazosin 
solution 
Donor cell 
Figure 3.2 Assembly of the Integrated Electrode System: 
Platinum electrode is inserted into one end of the salt-bridge 
to avoid a direct contact of the electrode with the drug 
solution. The potential drop across salt bridge was 
negligible. 
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Figure 3.3 TRZ and PRZ HPLC Chromatograms (in vitro study). Chromatograms (i a) shows 
an additional peak before the TRZ peak when current was passed through the drug solution 
using the Pt/Pt electrodes. However, no additional peak was noted when integrated 
electrodes were substituted for Pt/Pt electrodes (i b). Chromatogram (ii a) is from a 
blank sample; (ii b) is from the iontophoretically delivered TRZ sample (using 
integrated electrodes); and (ii c) is from a passively delivered TRZ sample. All samples 
were spiked with the internal standard (PRZ). The retention times of standard TRZ and 
PRH are 3.1 ± 0.2 and 5.6 ± 0.4 minutes respectively. Samples (i a) and (i b) were run 
at half sensitivity with respect to other samples 
1 is a degraded compound peak; 2 is a TRZ peak; and 3 is a PRZ peak 
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possible microbial contamination. The tubings were used within 
15 days of preparation. The electrode assembly is shown in 
Figure 3.2. 
3.3.5 Sample Treatment 
Frozen samples (SOO~L) from the receptor compartment were 
thawed to room temperature. Two samples of 100 ~L each were 
taken in 1 mL HPLC sample vials (Chromocol, Thrombi!!, USA) . 
To each of these vial 22 ~L of PRZ solution (16.4 ~g/mL of PRZ 
in 10% methanolic solution was prepared as the internal 
standard) was added, and mixed using a vortex mixture 
(Thermolyn Corporation, Iowa, USA) for 30 seconds. Ten micro 
-liters of the sample solution was injected into the HPLC 
system. Detection was done by UV detector at 245 rum. 
3.4 In Vivo Experiments 
3. 4 . 1 Animal Surgery 
Male Sprague Dawley rats (Av wt 256 g, n = 7 (test = 5, 
control= 2)) and Fuzzy rat {275 g, n = 1) were anesthetized 
by an intraperitoneal dose of 20% w/v urethane in saline. 
Initial injectable dose was 1.1 mg/Kg body weight and when 
necessary, the dose was titrated upwards but not exceeding 1.5 
mg/Kg body wt. Separate polypropylene catheters (1 mm 
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diameter) were inserted in the right carotid artery and left 
jugular vein. Microinjection pump (Carnegie Medicin, 
Stockholm, Sweden) was used to infuse 5 % w/v dextrose 
solution into the jugular vein at an initial rate of 5 ~L/min, 
and gradually increased and maintained at 22 ~L/min after 1 
hour post drug delivery. Blood sampling was done via the right 
carotid artery. Patency of the catheter was maintained with 
intermittent flushing with heparinized (10 USP unit/mL) 
saline. 
3.4.2 Animal Preparation 
Under anesthesia, body hair from a 2.5 cm2 surface area 
of the upper left and right hind legs of the same rat were 
removed by a cordless mustache trimmer (Ronson~, Hongkong) . 
Care was taken not to damage the skin. A pair of rectangular 
custom made plastic slabs (Figure 3.4) with a semi hemisphere 
cavity were glued to the shaved portion of the upper hind 
legs. The cavity was filled with 0.098% w/v TRZ solution. A 
single integrated electrode was inserted into each cavity on 
both hind legs through a small aperture provided at the top of 
the slab. 
custom built device 
cavity containing 
lmL of druq solution 
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Figura 3.4 ~r~tal Set up: In Vivo Study. The integrated 
electrodes were inserted into the cavity containing TRZ 
solution via the aperture at the top of the custom build 
device. The right carotid artery and the left jugular vein 
were cannulated for blood sampling and for dextrose infusion 
(not shown in the figure) . 
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3.4.3 Drug De1ivery 
A power supply in combination with the electronic circuit 
(Kepco, NY., USA) delivered a constant DC current of 0.25 mA 
was used. When the device was switched on, the polarity of the 
integrated electrodes reversed every 5.0 min. 
Initially, the drug delivery was done for 30 mins. But because 
of high mortality rate in rats due to cardiovascular effects 
associated with high plasma concentration of TRZ (50 ng/mL 
after 3.2 hr post delivery), the delivery time was decreased 
to 10 min. 
On each of five different work days, separate 
iontophoretic runs were carried out for 10 min. After 
delivery, the plastic slabs were removed and the residual drug 
was wiped off the skin with a swab of wet cotton. 
Blood samples (500 ~L) were collected at 0 hr, i.e., 
before delivery (blank) and 0.75, 1.5, 2.5, 3.5, 4.5, 5.5 and 
6. 5 hr after deli very in a polypropylene tubes containing 
about 5 ~L of heparin (1000 USP unit/m.L) . Under identical 
conditions, the passive drug delivery experiment was done on 
two animals i.e., same experimental set up but no current was 
passed through the system. After the experiments the animals 
were killed with an overdose of anaesthesia. 
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3.4.4 Sample Preparation and Treatment 
Samples were centrifuged at 1000 rpm for 15 min. The 
plasma obtained was stored at -20 °C. Before analysis, plasma 
samples were allowed to thaw to room temperature. The plasma 
samples (150 ~L) were then spiked with 50 ~L of PRZ solution 
(3.2 ~g/mL of PRZ was prepared in 10 % methanolic solution and 
used as an internal standard) and treated to solid phase 
extraction procedure using cyanopropyl column as described in 
section 2.7. 
Eluate obtained was evaporated to dryness with the aid of 
thermostat water bath maintained at 37°C and under a stream of 
nitrogen gas. The residue was reconstituted in 200 ~L mobile 
phases. Ten microliters of reconstituted sample was injected 
into the HPLC system. 
3.4.5 Chromatographic Conditions 
The chromatographic conditions were identical to in vitro 
studies except the fluorescence detector (Shimadzu 
Corporation, Kyoto, Japan) set at an excitation and emission 
wavelength of 345 and 400 nm respectively was used instead of 
the UV detector. 
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3.5 Resu1ts and Discussion 
3.5.1 HPLC Assay Ana1yses 
Tabl.e 3.1 Ca.libration Data: In Vitro Study. Interday 
variations were performed by analyzing following TRZ 
concentrations 0.084, 0.335 and 1.674 ~g/mL. 
Cone. phr phr phr phr phr phr phr phr mean 
phr 
f.lg/mL dla dlb d2a d2b d3a d3b d4a d4b 
0.084 0.127 0.125 0.137 0.121 0.127 0.130 0 .. 128 0.133 0.128 
0.164 0.200 0.204 0.201 0.212 0.192 0.212 0.210 0.225 0.207 
0.335 0.374 0.396 0.365 0.335 0.373 0.378 0.424 0.422 0.383 
0.837. 0.894 0.926 0.887 0.808 0.928 0.919 0.987 0.984 0.916 
1.674 1.850 1.920 1.640 1.600 1.920 1.923 1.951 1.984 1.848 
EQUATIONS OF CALIBRA~ION CURVES ON DIFFERENT WORRDAYS 
la PHR = 1.084.CONC + 0.0178; 1b PHR = 1.127.CONC + 0.0167 
2a PHR = 0.954.CONC + 0.5572; 2b PHR = 0.922.CONC + 0.0484 
3c PHR = 1.136.CONC + 0.0058; 3c PHR = 1.129.CONC + 0.0149 
4d PHR = 1.464.CONC + 0.0303; 4d PHR = 1.612.CONC + 0.0312 
CV SLOPE (m) (n=8) = 10 .. 98% 
Two way ANOVA F values for the interday variation performed 
on the concentrations 0.084, 0.335 and 1.674 f.lg/mL are: 
0.97, 1.28, 1.85. Critical F values (df. 1,3 at 0.05) = 10.1 
phr = peak height ratio of TRZ to PRZ; dla = phr at the 
start of the day one; 
dlb = phr at the end of the day one 
0 0.4 0.1 
jv = 1.0828.Conc-0.01681 
I R (sq) = 0.999, 
0.1 1 1 .• 
concentration (JJg/mL) 
73 
Figure 3.5 Ca1ibration Curve: In Vitro Study. A plot of PHR 
versus concentration of spiked standard solution of TRZ. Each 
point represents the mean ± SD for 4 work days <•> (n = 8). 
1.8 
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Table 3.2 Calibration Data: In Vivo Study. Precision of the analytical procedure 
determined by standard deviation and co-efficient of variation. 
CONC PEAK HEIGHT RATIO (TRZ/PRZ) MEAN ± SD %CV 
ng/mL day 1 day 2 day 3 day 4 day 5 day 6 day 7 
6.16 0.120 0.190 0.144 0.175 0.221 0.164 0.171 0.169 ± 0.03 17.9 
12.32 0.244 0.280 0.289 0.318 0.302 0.288 0.298 0.289 ± 0.02 7. 62 
24.64 0.607 0.570 0.600 0.544 0.559 0.550 0.563 0.570 ± 0.02 3.89 
61.6 1.550 1.487 1.583 1.555 1.300 1.246 1.456 1.495 ± 0.11 0.84 
123.2 2.626 2.548 2.760 2.631 2.510 2.464 2.651 2.598 ± 0.09 3.53 
WORK DAYS EQUATIONS OF CALIBRATION CURVES R2 
1 PHR = 0.0216.CONC + 0.04355 98.9 
2 PHR = 0.0226.CONC + 0.04621 99.4 
3 PHR = 0.0207.CONC + 0.06191 99.2 
4 PHR = 0.0213.CONC + 0.07121 99.1 
5 PHR = 0.0197.CONC + 0.08063 99.9 
6 PHR = 0.0196.CONC + 0.04793 99.7 
7 PHR = 0.0214.CONC + 0.05290 99.7 
CV SLOPE (m) (n=7) = 4.66% 
0 
~ - 0.02095.Conc + 0.0608] 
(A (eq) • 0.997( 
-
-
- 100 
concentration TRZ (nglml) 
15 
,. 
Figure 3.6 Calibration Curve: In Vivo Study. The values shown 
are mean ± SD (n = 7). 
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For in vitro studies, standard analysis (Table 3.1) of TRZ in 
the concentration range of 0. 08 J.J.g/m.L - 1. 68 JJ..g/m.L were 
constructed in duplicate for each of the five work days. The 
PHR of TRZ to PRZ was linearly related to the concentration of 
TRZ. Correlations of determination (R2 ) for the linearity for 
all standard curves were greater than 0.99. The 
reproducibility of the analytical procedure was determined by 
two way ANOVA. The between day and inter day variation were 
not significant (p > 0.05). The coefficient of variation in 
slopes was less than 11% (n = 8) (Table 3.1). The high value 
is probably due to analytical error in the standard sample 
( 61 • 6 ng I mL) • 
For in vivo studies, the standard curves of TRZ in the 
concentration range of 6.6 - 123.2 ng/mL were constructed on 
each of the work day (n = 7} . The sensitivity of the assay 
procedure is 0. OS ng/ml at a signal to noise ratio of 6. 
However, the phr was easily determined at three times the 
noise level for the passive delivery (Table 3.3). 
The PHR of TRZ to PRZ was linearly related to the 
concentration of TRZ (R2 > 98.8) . Reproducibility of the 
analytical procedure was determined by co-efficient of 
variation of the slopes (less than 5% (n = 7)) (Table 3.2). 
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3 . 5 . 2 Pharmacok.inetic Ana.l.ys.is 
The elimination rate from the central compartment is 
0.0304 hr-1 • The plasma half life is 2.25 hr and compares well 
with the existing literature value of 2.3 hr (Chang and Bauer, 
1991) . The clearance of the drug from systemic circulation is 
0. 009 L/hr. Assuming complete absorption, the area under curve 
( (AUC) a- is 88.58 ng .hr/mL} was calculated from the 
trapezoidal rule. The residual area was determined from Cn/ke 
where, Cn is the last observed plasma concentration. Since 
the volume of distribution is best estimated from iv dose, the 
estimation of iontophoretic dose and the transport efficiency 
are therefore approximate. (The volume of distribution is 
based on ip dose extrapolated from section 2.8.2.) It may be 
necessary to validate the results with iv dose determination. 
(AUMC} • Dose 
= 
Dose = 
(AUC) 2 
(AUC) 2 • Vd 
(AUMC) 
(Gibaldi and Perrier, 1982) 
Vd = av wt of rat(0.256 Kg)x 1.17 L/Kg = 300 mL 
Dose = 
(88.58) 2 X 300 mL 
279.11 
= 8 • 4 3 X 10 -6 g 
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If id is the strength of the current carried by the drug ion, 
then by Faraday's law: 
Dose. (Faraday's constant). (molecular charge) 
(molecular weight of terazosin) . (time of application) 
8 . 4 3 X 1 0-6 X 9 6 50 0 X 1 
= 3. 5 X 10-6 A 
387.44 X 600 
3. 5 X 10 -a A 
transport number (tr) = = 
total current 0.25 X 10 -J A 
tr = 0. 0139 
efficiency(~ %) = tr x 100 = 1.39 
3. 5. 3 Drug Deli very 
The outermost layer of the skin, the stratum corneum has 
been considered as the rate limiting barrier to the ionic 
permeant (Ruddy and Hadzija, 1995). Stratum corneum is 
composed of dead keratinized cells, embedded in a 
multicellular lipid matrix which is heterogeneous and 
lipophilic in nature. Depending upon the physiological 
properties of the drug, the permeant will follow the pathway 
of least resistance (Flynn, 1990) . 
The TRZ flux across skin as a function of t~e increased 
linearly with time and reached maximum in about 6 hrs (Figure 
3.7). A£ter that, there is steady decrease in flux with time. 
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Figura 3.7 TRZ Flux Across Rat Skin after 24 hr delivery. The values shown are mean + 
SD (n = 5) . • Iontophoretic delivery A Passive delivery 
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It was also noted that there is no abnormal increase in drug 
flux suggesting that current density of 0.03 mA/cm2 did not 
produce any gross skin damage. If the skin was damaged, an 
abnormal increase in flux would have been noted. Since the 
drug in reservoir was infinite, the decline in curve could not 
be easily explained. Further sampling points between 8 to 24 
hours probably would give a better estimation of the drug 
flux. Alternatively, the drug transport could be studied by 
the plot of cumulative amount of TRZ delivered across skin as 
a function of time (Figure 3.8). The curve resembled a curve 
typical of an infinite dose. That is, on increasing drug 
delivery beyond 24 hours, the amount delivered across skin 
would be expected to increase linearly till the near depletion 
of the drug from the reservoir, and the curve would assume a 
sigmoidal shape. It was also noted that there is no abnormal 
increase in drug delivery suggesting that the current density 
of 0.03 mA/cm2 did not produce any gross skin damage. If the 
skin was damaged, an abnormal increase in delivery would have 
been noted. From the x axis intercept of the linear portion of 
the plot the lag time required to reach the steady state was 
obtained. The lag time was negligibly small (-2 min) 
suggesting that iontophoresis can rapidly overcome the rate 
limiting barrier, the stratum corneum. In iontophoresis, the 
lag time is generally very short. These very short lag 
I 11 
time (hr) 
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• 
Fiqure 3.8 Cumulative Delivery of TRZ Across Excised Rat Skin. The values shown are mean 
± SD. Iontophoresis was done in diffusion cells for 24 hrs using: Pt/Pt electrodes and 
0.25 mA DC reversing current. • Iontophoretic delivery A Passive delivery 
82 
time have raised questions about the nature of the barrier 
which could be breached very quickly (Singh and Roberts, 
1993). This led to several in vivo experiments (Haak and 
Gupta, 1994; Meyer eta~., 1989). In these experiments the 
correlation of drug concentration profile by TI and other 
parenteral routes suggest that electrically assisted 
absorption is rapid and the pharmacokinetics is similar to the 
parenteral route (Haak and Gupta, 1994; Meyer et al., 1989). 
It is believed that the electric field propels the ionic 
molecule down its transport pathway and its motion being less 
impeded because it cannot partition into the abundant lipid 
moiety along its route. Aiter the passage through the stratum 
corneum, the drug may accumulate in the dermis where they are 
absorbed into the blood circulation, and the rate of drug 
absorption depends upon the dermal blood perfusion (Singh et 
al., 1994) • 
As evident from our results (Figure 3.8, Table 3.3), the 
plasma level of TRZ beyond the delivery time is unlike the 
parenteral delivery which is always associated with Lmmediate 
decline in blood levels following termination of delivery. The 
initial drug release rate exceeds the elimination rate till 
about 1.5 hr. Thereafter, the elimination rate exceeds the 
absorption rate. This lends support to the establishment of a 
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reservoir (Siddiqui and Chein, 1987; Kari et al., 1986) in 
the skin. Comparing the slopes of the elimination phases of 
TRZ after TI (~ = 0.308 hr-1 ; Figure 3.9) and that obtained by 
oral absorption (ke = 0.301 hr-1 ; cr. Chang et; al., 1984) in 
rats suggest that the elimination phase of the two is 
superimposable. 
Skin environment could also influence drug absorption. 
There is a possibility of drug delivery in the glands (Gibson 
1974) . The pH of the gland pore on skin is about 4-5, while in 
dermis it is 7.0. The change in pH may affect the terazosin 
solubility (pKa 7.1) making it more lipid soluble (Burnette 
and Ongipiattanakul, 1987; Siddiqui et al., 1987). In such 
cases, movement of the drug across the sweat gland would be 
the rate limiting step. In experiments conducted by Riviere et 
al. (1991}co-administration of vasodilator or a vasoconstrictor 
correspondingly increased and decreased plasma concentration 
of lidocaine by its direct on the large blood vessels. 
Terazosin is a peripheral vasodilator (Kyncl, 1986) and 
iontophoresis as such produces vasodilation in the 
capillaries. (The clinical example for the latter effect is 
the erythema observed after the iontophoresis of tap water 
(Holzle and Alberti, 1987) . Considering these effects and the 
short duration of delivery, rapid enormous delivery exceeding 
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Figure 3. g TRZ Plasma-Time-Concentration Simulation in Sprague 
Dawley Rata (n = 5). The values shown are the mean values. The 
curve is the best fit line obtained from computer simulation. 
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Table-3.3 TRZ Plasma-Time- Concentration Profile after a 10 min Iontophoretic and 
Passive Delivery in Rats 
BLOOD 
SAMPLING CONCENTRATION OF TRZ (ng/mL) 
TIME spd-!1* spd-!2 spd-!3 spd-!4 spd-!5 mean spd spd-P1 spd-P2* mean 
spd fri1* spd P 
0.00 o.oo 0.00 0.00 0.00 0.00 0.00 0.00 o.oo o.oo o.oo 
0.75 4.68 4.18 3.22 1.98 4.17 3.65 3. 75 0.00 0.00 0.00 
1.5 5.46 14.86 9.00 27.42 6.58 8.66 9.91 0.00 0.57 0.30 
2.5 10.70 5.00 4.74 5.37 2.60 5.68 20.20 o.oo 0.04 0.01 
3.5 6.20 2.65 4.21 1.67 1.02 3.34 2.13 o.oo 0.08 0.04 
4.5 4.79 2.25 3.22 1.26 1.60 2.62 1.51 0.00 0.07 0.04 
5.5 2.46 2.04 2.98 1.09 1.36 1.99 0.37 0.00 0.07 0.04 
6.5 0.00 0.64 2.53 1.00 0.89 1.00 0.00 o.oo 0.03 0.01 
* 
spd-!1 = The suffix 11 refers to iontophoretic delivery in Sprague Dawley rat No 1. 
fr = Fuzzy rat; spd P2 refers to passive delivery in Sprague Dawley rat No 2. 
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the vascular uptake is unlikely. If this is not true, then 
some of the drug if not all must appear Lmmediately in blood. 
This was not evident at 20 min post drug delivery. Several 
explanation can be forwarded to explain this effect. It is 
possible that the drug is delivered in apocrine gland, where 
the blood perfusion is unable to extract the drug. The 
evidence comes from the clinical evaluation of dermatological 
disorder of miliaria (Hirksman et al., 1985) where the ecrine 
gland (analogous comparison as rat do not have ecrine gland 
over its general skin surface) closes its aperture due to 
occulsion, and the gland wall being non leaky causes the 
accumulation of sweat in the duct. The delivery of 
anticholinergic drug pilocarpine in the diagnosis of cystic 
fibrosis is itself a suggestion of electric current traveling 
down the ecrine gland (Gibson, 1975) . High current strength 
and increasing hydration may result in the closure of the 
shunt route as seen in some cases (Holzle and Alberti, 1987; 
Millard and Barry, 1988). In such instances the paracellular 
transport through the lipid bi-layer region would be the 
predominant pathway in the absence of low resistant pores (Lee 
e t al . , 19 9 6) . 
The pilomotion and the vasoconstrictor responses seen 
after 30 sec iontophoresis of phenylephrine support the above 
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belief (Horniquest et al., 1984}. The pilomotion effect was 
seen only after the vasoconstrictor response and usually at 
higher current strength. But both responses persisted beyond 
30 mins which may not be due to depot effect. Rather the 
drug's intrinsic affinity at its receptor may play an 
important role. (The pilomotion and the vasoconstrictor 
response are mediated by a receptors.} Jodoul et al. (1995) 
have shown that the amount of ionic drug in the skin is the 
same for different duration of drug delivery, suggesting that 
the initial amount of drug delivered was sequestered at the 
skin binding sites. Once the binding sites are saturated it is 
possible that the excess drug is then available for the 
systemic uptake. 
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Figure 3.10 TRZ and PRZ HPLC Chromatograms After a 10 mdnutes Iontophoresis of TRZ (in 
vivo study). Chromatogram (a) is from a blank plasma sample. Chromatogram (b) is from 
the sample collected at 1.5 hr post iontophoresis and (c) is from the plasma collected 
at 1.5 hour post passive delivery. All samples were spiked with the internal standard 
(PRZ). The retention times of standard TRZ and PRZ are 3.1 ± 0.2 and 5.6 ± 0.4 minutes 
respectively. 
1 is TRZ peak, 2 is PRZ peak 
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3. 6 Summary of Iontophoretic Study 
The results from drug delivery study suggest that (1) the 
delivery of terazosin into the skin is enhanced by 
iontophoresis in comparison to passive delivery (Table 3.3), 
and the use of salt-bridge-platinum electrodes prevented 
terazosin degradation in the presence of electric current. (2) 
A depot formation of terazosin is seen in vivo after 10 minute 
iontophoretic delivery in rats. The site of depot formation is 
unknown. 
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4.0 General Discuss~on 
The analytical procedure developed for terazosin was 
sensitive, precise, and was employed in the solid phase 
extraction study. The recovery of terazosin from rat plasma 
using cyanopropyl columns is high and it is possible to 
improve the extraction efficiency of the reused columns by 
altering the column wash cycle. 
The analytical procedure developed was applied for 
terazosin but not for the isolation and characterization of 
its drug metabolites. The single dose pharmacokinetic study 
was undertaken to demonstrate the applicability of the 
analytical procedure rather than a detailed study. 
The experiments from the in vivo delivery suggest that it 
is possible to take advantage of a drug reservoir effect in 
skin to establish intradermal depot of therapeutically useful 
compounds, which are then slowly absorbed over prolong period. 
A similar depot effect was seen in vivo with the iontophoresis 
of bretylium tosylate (MW 414) (Kellog et al., 1989), which 
selectively abolished the vasoconstrictor response in a small 
skin area without eliciting systemic responses. A prolonged 
effect may reduce the frequency of drug administration. 
However, further experLments may be required to validate the 
reservoir effect. For example, the simulation of intradermal 
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skin depot as in the iontophoresis of terazosin by the 
subcutaneous injection may shed more light, but the site of 
depot formation by the two processes may differ from one 
another. A mathematical determination of absorption rate 
constants could provide an alternate and a better estimate. 
To Lffiprove the patient compliance, the applied current 
density, the area of application, the pH and the ionic 
strength of the terazosin solution, and the current amplitude 
and frequency of DC reversing current can be optimized to 
produce a maximum delivery with minimum side effects (Huang 
et al., 1996a; 1996b) such as tingling, itching, slight 
pricking and erythema. Skin resistence which is highly 
variable depend upon factors such as degree of hydration, hair 
and sweat gland density, which can lead to high current 
density across pores than at the skin surface resulting in 
current induced skin damage. This problem is avoided by 
increasing current strength gradually from zero to the desired 
strength and then maintaining it irrespective of changes 
brought in the skin impedance. That is, a constant current 
strength rather than constant voltage will be used. By 
empirical determinations a current density of 0.5 mA/10 cm2 
can be easily applied to the skin (Sanderson eta~., 1989). 
Since temporary skin changes accompany all iontophoretic 
92 
procedures, an optimum time period would be required before a 
second dose is administered at the same site, or new skin 
sites may be selected. 
Delivery of a drug at the site of action with minimum 
side effects is one of the advantages of iontophoresis over 
oral delivery. Unlike the problems associated with an oral 
route, iontophoresis is independent of gastrointestinal 
emptying rate and the amount of a drug delivered is easily 
controlled by varying the current strength or the time of 
delivery, thus reducing systemic toxic effect. Iontophoresis 
reduces intra- subject variation (similar drug fluxes were 
obtained across human thigh skin varying in skin hair density 
{Burnette and Ongipiattanakul, 1987) and inter species 
variation (comparable fluxes were noted in hairless rats, 
fuzzy rats, human, pig and rabbit skin (Siddiqui and Chien, 
1987; Phipps et al., 1989}. 
Initial attempts in our laboratory to develop the Kim and 
Chung (1992) L5/L6 spinal nerve ligation rat model of causalgia 
have been unsuccessful. It appears that the age of the rat 
(Chung et al., 1995) and tightness of the ligature are 
critical for the animal's robust behavior (allodynia, 
hyperalgesia) that is the characteristic of causalgia. 
Presently, no animal models that is truly representative of 
93 
the human condition exist, and therefore, further experimental 
work is necessary to perfect the model. The safety, efficacy 
and toxicity study in a rat model and in at least three other 
animal species would be carried out before a phase I human 
study is initiated. 
The fall in blood pressure after delivery may be 
monitored and could be used as an index to optimize the dose 
as to achieve a local therapeutic action. A dramatic fall in 
blood pressure will indicate that smaller iontophoretic dose 
is required which could be obtained either by decreasing 
current strength or the time of delivery or both. Once the 
dose is predetermined, the dose can be programmed to the 
patient's need. 
The size of a device could be reduced to that of a 
wristwatch, which could then be easily strapped distally to 
the site of injury. Any error that arises in the working of 
the iontophoretic system can be indicated by introducing 
electronic features. But the cost of electrodes and batteries 
required to sustain the circuit system may make the device 
expensive. One way of compensating cost is to improve the 
efficiency of the delivery system. Extraneous ions that are 
introduced into the drug reservoir compete with drug ions for 
transport resulting in decreased iontophoretic efficiency. An 
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efficiency of 1. 39% for terazosin, although comparable to 
compounds of similar molecular weight(Singh et al., 1984) is 
significantly low, and the needs for better designs are 
warranted. Penetration enhancers increased the drug flux of 
large molecular weight compounds, but the combination of 
iontophoresis and chemical adjuvants was ineffective for low 
molecular weight compounds (Hirvonen et al., 1993) like 
terazosin. 
The main disadvantage of iontophoresis is that its long 
term effects of drug and iontophoresis on skin are still to be 
evaluated. However, the system when used properly can be 
extremely useful. The administration of lidocaine in the 
anaesthesia of ear and the iontophoresis of pilocarpine in 
the diagnosis of cystic fibrosis are generally accepted to be 
a safe procedure (Echols et al., 1975; Gibon, 1975}. As with 
other novel delivery system, the acceptability of the device 
depends upon the patient compliance. The management of so far 
unmanageable pain as in causalgia may enhance the utility 
value of the device which may outweigh its disadvantages. 
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